Ultrastructural Analysis of Edelfosine-treated Trypomastigotes and Amastigotes of Trypanosoma Cruzi

Overview

Journal Parasitol Res

Specialty Parasitology

Date 2006 Jul 21

PMID 16855821

Citations 9

Authors

R M Santa-Rita

H S Barbosa

S L de Castro

Affiliations

Soon will be listed here.

Abstract

We have previously reported that epimastigote forms of Trypanosoma cruzi treated with the lysophospholipid analogues (LPAs) edelfosine (ET-18), ilmofosine, and miltefosine suffered alterations in plasma membrane, mitochondrion, and lipid synthesis. In this work, ET-18 induced membrane damage in trypomastigotes and amastigotes. Incubation of epimastigotes and trypomastigotes with the three LPAs led to membrane permeabilization, which was abolished by serum addition. Treatment for 24 h in culture medium interfered the with mitochondrial status of epimastigotes, with no effect in trypomastigotes, in agreement with ultrastructural data. LPAs induced alterations in the plasma membrane of the three forms of T. cruzi and in the mitochondria of epimastigotes, suggesting that these organelles are potential targets of these analogues.

Citing Articles

Repositioning drug strategy against Trypanosoma cruzi: lessons learned from HIV aspartyl peptidase inhibitors.

Sangenito L, dAvila-Levy C, Branquinha M, Dos Santos A Mem Inst Oswaldo Cruz. 2022; 117:e210386.

PMID: 35293428 PMC: 8925306. DOI: 10.1590/0074-02760210386.

Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi.

Fonseca-Berzal C, Aran V, Escario J, Gomez-Barrio A Parasitol Res. 2018; 117(11):3367-3380.

PMID: 30232605 DOI: 10.1007/s00436-018-6084-3.

Evaluation of the effect of miltefosine on Trichomonas vaginalis.

Rocha D, de Andrade Rosa I, De Souza W, Benchimol M Parasitol Res. 2013; 113(3):1041-7.

PMID: 24363204 DOI: 10.1007/s00436-013-3738-z.

Soulamarin isolated from Calophyllum brasiliense (Clusiaceae) induces plasma membrane permeabilization of Trypanosoma cruzi and mytochondrial dysfunction.

Rea A, Tempone A, Pinto E, Mesquita J, Rodrigues E, Silva L PLoS Negl Trop Dis. 2013; 7(12):e2556.

PMID: 24340110 PMC: 3854968. DOI: 10.1371/journal.pntd.0002556.

4-Acetoxydolastane diterpene from the Brazilian brown alga Canistrocarpus cervicornis as antileishmanial agent.

Santos A, Britta E, Bianco E, Ueda-Nakamura T, Prado Dias Filho B, Pereira R Mar Drugs. 2011; 9(11):2369-2383.

PMID: 22163190 PMC: 3229239. DOI: 10.3390/md9112369.

References

Santa-Rita R, Henriques-Pons A, Barbosa H, de Castro S . Effect of the lysophospholipid analogues edelfosine, ilmofosine and miltefosine against Leishmania amazonensis. J Antimicrob Chemother. 2004; 54(4):704-10. DOI: 10.1093/jac/dkh380. View

Saraiva V, Gibaldi D, Previato J, Mendonca-Previato L, Bozza M, Freire-de-Lima C . Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi. Antimicrob Agents Chemother. 2002; 46(11):3472-7. PMC: 128733. DOI: 10.1128/AAC.46.11.3472-3477.2002. View

Noseda A, White J, Godwin P, Jerome W, MODEST E . Membrane damage in leukemic cells induced by ether and ester lipids: an electron microscopic study. Exp Mol Pathol. 1989; 50(1):69-83. DOI: 10.1016/0014-4800(89)90057-9. View

Vagnetti D, Mancini A, Santarella B, Binaglia L . Effect of alkyl-lysophospholipid analogs on the morphology of a murine lymphoma cell line. J Submicrosc Cytol Pathol. 1990; 22(3):415-24. View

Croft S, Snowdon D, Yardley V . The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother. 1996; 38(6):1041-7. DOI: 10.1093/jac/38.6.1041. View

Andreesen R, Modolell M, Oepke G, Common H, LOHR G, MUNDER P . Studies on various parameters influencing leukemic cell destruction by alkyl-lysophospholipids. Anticancer Res. 1982; 2(1-2):95-100. View

Lohmeyer M, Workman P . The role of intracellular free calcium mobilization in the mechanism of action of antitumour ether lipids SRI 62-834 and ET18-OMe. Biochem Pharmacol. 1993; 45(1):77-86. DOI: 10.1016/0006-2952(93)90379-b. View

Santa-Rita R, Santos Barbosa H, Meirelles M, de Castro S . Effect of the alkyl-lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi. Acta Trop. 2000; 75(2):219-28. DOI: 10.1016/s0001-706x(00)00052-8. View

de Castroa S, Santa-Ritaa R, Urbinab J, Croftc S . Antiprotozoal lysophospholipid analogues: a comparison of their activity against trypanosomatid parasites and tumor cells. Mini Rev Med Chem. 2004; 4(2):141-51. DOI: 10.2174/1389557043487439. View

10.

PETERSEN E, Kelley E, MODEST E, Burns C . Membrane lipid modification and sensitivity of leukemic cells to the thioether lipid analogue BM 41.440. Cancer Res. 1992; 52(22):6263-9. View

11.

Santa-Rita R, Lira R, Barbosa H, Urbina J, de Castro S . Anti-proliferative synergy of lysophospholipid analogues and ketoconazole against Trypanosoma cruzi (Kinetoplastida: Trypanosomatidae): cellular and ultrastructural analysis. J Antimicrob Chemother. 2005; 55(5):780-4. DOI: 10.1093/jac/dki087. View

12.

de Castro S, Meirelles M, Oliveira M . Trypanosoma cruzi: adrenergic modulation of cyclic AMP role in proliferation and differentiation of amastigotes in vitro. Exp Parasitol. 1987; 64(3):368-75. DOI: 10.1016/0014-4894(87)90049-x. View

13.

Lira R, Contreras L, Rita R, Urbina J . Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole. J Antimicrob Chemother. 2001; 47(5):537-46. DOI: 10.1093/jac/47.5.537. View

14.

Rodriques Coura J, de Castro S . A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz. 2002; 97(1):3-24. DOI: 10.1590/s0074-02762002000100001. View

15.

Heesbeen E, Rijksen G, van Heugten H, Verdonck L . Influence of serum levels on leukemic cell destruction by the ether lipid ET-18-OCH3. Leuk Res. 1995; 19(6):417-25. DOI: 10.1016/0145-2126(95)00008-c. View